Trial Profile
A Phase I, Single-center, Open-label, Single-dose Study to Evaluate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of Orally Administered SUVN-G3031 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 May 2020
Price :
$35
*
At a glance
- Drugs Samelisant (Primary)
- Indications Narcolepsy
- Focus Pharmacokinetics
- Sponsors Suven Life Sciences
- 12 May 2020 Results of NCT04072380 and NCT02342041 assessing Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, published in the Clinical Drug Investigation.
- 21 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Sep 2017.
- 21 Sep 2017 Status changed from recruiting to completed.